In contrast, TRAILv-KHYG-1 cells offer the potential for targeted and sustained delivery of TRAIL specifically to tumour cells, potentially minimizing systemic side effects and enhancing therapeutic efficacy. This evidence concerns the gene TNFSF10 and neoplasm.